Information to Applicants about the GARDASIL® Access Program
Under the GARDASIL® Access Program Merck & Co., Inc. (Whitehouse Station, NJ, USA) has pledged to
make available at least 3 million doses of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11,
16, 18) Vaccine, Recombinant] over the next five years for use in projects in eligible low income countries
throughout the world. GARDASIL® helps prevent cervical cancer caused by HPV types 16 and 18, which
Historically, there has been a significant delay between the introduction of new vaccines in developed and
developing countries. The GARDASIL® Access Program strives to overcome the challenges to achieving
vaccine access in developing world nations and empowers resource-poor nations and their partners to
develop programs to bring this vaccine to people in need.
The GARDASIL® Access Program will provide GARDASIL® to programs in eligible countries to allow
countries to gain experience in the implementation of such programs. It does not aim to cover nationwide
HPV vaccine programs. The program will draw upon the learnings and experiences from participating
organizations and seek to contribute to knowledge on how to successfully implement vaccine access
The GARDASIL® Access Program, which is planned to run over a 5-year period, is made possible by a
pledge from Merck & Co Inc. (Whitehouse Station, NJ, USA), and is overseen by Axios Healthcare
Development (AHD), a US non-profit organization. AHD administers the donation program, reviews and
approves applications, and ensures prompt delivery of the vaccine to the recipients, with the technical
assistance of Axios International, a public health consultancy specializing in developing and emerging
GARDASIL® will be made available to eligible institutions that are nationally recognized and meet the
GARDASIL® Access Program eligibility criteria. The qualifying institutions could fall under any of the
NGOs or charitable organisations involved in vaccination services and/or cancer management
Institutions will be required to present a letter of support from the Ministry of Health.
The GARDASIL® Access Program will provide information and guidelines for health care workers on how to
GARDASIL® is a registered trademark of Merck & Co., Inc, Whitehouse Station, NJ, U.S.A
What is GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant]?
GARDASIL® is a non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like
particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The quadrivalent HPV VLP
vaccine is a sterile liquid suspension that is prepared by combining the adsorbed VLPs of each HPV type
and additional amounts of the aluminum containing adjuvant and the final purification buffer. The VLPs
contain no viral DNA, they cannot infect cells, reproduce or cause disease.
GARDASIL® is licensed by FDA for use among females 9 to 26 years of age to prevent cervical cancer,
precancerous or dysplastic lesions, and genital warts caused by HPV types 6, 11, 16 and 18.
GARDASIL® is contraindicated in individuals who are hypersensitive to the active substances or to any of
The health care provider should inform the patient, parent or guardian that vaccination does not
substitute for routine cervical cancer screening. Women who receive GARDASIL® should continue to
undergo cervical cancer screening per standard of care.
GARDASIL® is not recommended for use in pregnant women.
GARDASIL® may not result in protection in all vaccine recipients. GARDASIL® is
not intended to be used for treatment of active genital warts; cervical cancer; CIN, vulvar interepithelial
neoplasia (VIN), or vaginal interepithelial neoplasia (VaIN). GARDASIL® has not been shown to protect
In clinical studies for GARDASIL®, vaccine-related adverse experiences that were observed at a
frequency of at least 1.0 percent among recipients of GARDASIL® and also greater than those observed
among recipients of placebo, respectively, were pain, swelling, erythema, fever, nausea, pruritis and
dizziness. In addition, common post-marketing reports include vomiting and syncope.
GARDASIL® is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL® should be
administered in three separate intramuscular injections in the upper arm or upper anterior thigh over a six-
month period. The following dosage schedule is recommended: first dose at elected date, second dose two
months after the first dose and the third dose six months after the first dose.
Please refer to the Prescribing Information for more information on GARDASIL®.
How to Apply
Axios International will send out notifications to institutions to submit their proposals/applications twice a year. For 2008, the proposal submission deadline is 1st of September 2008. Applicants who miss the
deadline for proposal submission may wait for the next call. However, they may submit their proposals on
the understanding that they will only be reviewed at the next board meeting. Proposals received after the
deadline will be kept until the next submission date is due.
Activity Deadline / Time Frame
Applicants interested in applying for GARDASIL® must complete a simple application that clearly
demonstrates their proposal on how the institution intends to implement the program, ensure safety injection
procedures and conduct monitoring and evaluation process. The application/proposal will be reviewed by a
team of competent and experienced independent reviewers and an AHD Advisory Board.
Applications can be accessed on any of the following websites:
• Request the application by fax or post to Axios International.
For more information about GARDASIL® Access Program and the eligible countries
You may also download and print out this form from this web site. If you do not have access to the Internet,
or would like an electronic copy of this document, please contact Axios International.
Email, fax or post The review process
As soon as the application is received by Axios International, a rapid screening will be performed to ensure
that the information provided is complete. Applicants will be contacted within five (5) days of receipt of their
application and will be informed about the progress of their file. Additional information may be requested at
this stage. If the application is complete, independent experts, commissioned by AHD, will review the
proposal and give their recommendations to the Advisory Board. The Advisory Board will make a final
review of the application/proposal at their bi-annual board meeting and give a recommendation to AHD.
1. The proposal is satisfactory and the Institution is recommended for inclusion in the GARDASIL®
2. Additional information or clarifications are required before recommendation can be made
When the application is approved
The applicant will receive an official letter to confirm that AHD has approved the Institution for inclusion in
the GARDASIL® Access Program. Details concerning the quantity of GARDASIL®, timescale, shipping
schedules and shipping procedures will be defined in the approval note. The applicant should provide the
exact shipping address and any other relevant information necessary for sending the vaccine to the country
when completing the application. The applicant will be notified of shipment schedule as soon as the
information is received from the shipper.
The administration and use of GARDASIL® requires the donation product to be approved for use in the
country. If the vaccine is not approved for use, the applying institution must have a special import license
and/or a waiver letter from the government to import this donation.
AHD, supported by Merck & Co., is offering GARDASIL® free-of-charge and will cover the shipping costs
and insurance up to the indicated port of entry in the countries. The recipient is responsible for all other
Dialogue and Reporting
There will be an ongoing dialogue with institutions participating in the program. In addition, a progress report
should be sent to AHD 6 months after receipt of the vaccines. However the institution can submit an earlier
report in case of a need for a re-supply. A standard template will be provided to each institution to facilitate
the reporting process. Main Indicators tracked will concern GARDASIL® data consumption, number of
people vaccinated (1st, 2nd and 3rd injections), number of centres involved, etc. The information from the
application and the date of the regular progress reports will be entered into a database maintained by AHD.
This database will provide data on the number of institutions participating in the GARDASIL® Access
Program, the reported number of patients receiving GARDASIL® in each country and other relevant
Re-Supply of GARDASIL®
Once an institution has received the first donation of GARDASIL®, the request for re-supply will be automatic
based on numbers reached compared to those approved by the advisory board. The donor commits to
provide the complete dose of GARDASIL® (3 schedules) to all patients that have received the first dose
through the application process. The institution will be asked to provide a progress report detailing the
quantity of GARDASIL® requested, the quantity used and number of patients reached as justification. AHD
reserves the right to amend requests based on information collected on the program and usage of product.
The following countries are eligible to participate in the program:
Volume 5, No. 1 • April 2003 Helping Orthodontic Patients In This Issue Achieve Optimum Oral Health It is well established that an individual with orthodontic applianceshas a unique and challenging self-care situation. From a practical perspective, bands, brackets and other hardware are difficult to effectively clean resulting in an increase in plaque accumulat
Master data/monograph – Salvia officinalis (Salbei) Master data ingredient / monograph Ingredient/plant: Description: Common sage (Salvia officinalis) is a small evergreen subshrub ( a woody perennial plant), with woody stems, grayish leaves, and blue to purplish flowers native to southern Europe and the Mediterranean region. It is much cultivated as a kitchen and medicin